Antimicrobial Activity of Doripenem Tested Against Leading Bacterial Pathogens: Results from a Latin American Surveillance Study (2003-2006)
Data
2008-10-01
Autores
Gales, Ana Cristina 
Sader, Helio Silva
Tipo
Artigo
Título da Revista
ISSN da Revista
Título de Volume
Resumo
Carbapenems have been the therapeutic choice for empirical treatment of serious infections when multidrug-resistant Gram-negative organisms are suspected. Doripenem is a parenteral 1-beta-methyl-carbapenem that was recently approved in the USA for complicated urinary tract and intra-abdominal infections. We performed a longitudinal surveillance study on the in vitro activity of doripenem and comparator agents against patient isolates from Latin America. Consecutive, non-duplicate bacterial isolates (13,809) were collected from patients in 10 medical centers in Brazil (45.2%), Chile (21.1%), Argentina (17.9%), Mexico (12.9%) and Venezuela (2.9%). Isolate identifications were confirmed and susceptibility testing was performed using reference methods at a central laboratory (JMI Laboratories, North Liberty, IA). Doripenem and meropenem were the most active compounds tested against E. coli and Klebsiella spp. (MIC(90) values, <= 0.12 mu g/mL), including against those strains with ESBL phenotypes (15.2% of E. coli and 44.9% of Klebsiella spp.). All Enterobacter spp. strains were inhibited at <= 4 mu g/mL of doripenem, meropenem or imipenem; only ertapenem was less active (94.8% susceptible). Furthermore, only 86.6 and 77.0% of Enterobacter spp. strains were susceptible to amikacin and polymyxin B, respectively. Doripenem and meropenem were equally potent against R aeruginosa (MIC(50) 1 mu g/mL) and Acinetobacter spp. (MIC(50) 2 mu g/mL); however, doripenem inhibited a greater number of R aeruginosa (78.1%) at MIC values of <= 4 mu g/mL compared to meropenem (70.9%) or imipenem (67.9%). Moreover, doripenem inhibited 34.0% of imipenem-non-susceptible P aertiginosa isolates at MIC values <= 4 mu g/mL. Doripenem inhibited all oxacillin-susceptible staphylococci and S. pneumoniae, including penicillin-resistant strains, at <= 2 mu g/mL. In summary, doripenem showed potent activity against Enterobacteriaceae (including ESBL- and/or AmpC-producing strains), oxacillin-susceptible staphylococci and streptococci isolated in Latin American hospitals participating in the international doripenem surveillance program. Doripenem activity was also comparable to that of other carbapenems against P aeruginosa and Acinetobacter spp. Given limited therapeutic choices available, doripenem shows a promising broad-spectrum that should prove useful in geographic regions with problematic emerging resistances.
Descrição
Citação
Brazilian Journal Of Infectious Diseases. Salvador: Contexto, v. 12, p. 59-66, 2008.